Geburtshilfe Frauenheilkd 2015; 75(12): 1232-1238
DOI: 10.1055/s-0041-109717
Guideline
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Expertsʼ Opinion on the Prenatal Therapy of Congenital Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency – Guideline of DGKED[*] in cooperation with DGGG (S1-Level, AWMF Registry No. 174/013, July 2015)

Adrenogenitales Syndrom mit 21-Hydroxylase-Defekt (AGS) – Stellungnahme zur pränatalen Therapie. Leitlinie der DGKED mit Beteiligung der DGGG (S1-Level, AWMF-Registernummer 174/013, Juli 2015)
H. G. Dörr
1   Kinder- und Jugendklinik des Universitätsklinikums Erlangen, Erlangen
,
G. Binder
2   Univ.-Kinderklinik Tübingen, Sektion Endokrinologie, Tübingen
,
N. Reisch
3   Medizinische Klinik und Poliklinik IV. Klinikum der Universität München, München
,
U. Gembruch
4   Abteilung für Geburtshilfe und Pränatalmedizin der Universität Bonn, Bonn
,
P. G. Oppelt
5   Kinder- und Jugendgynäkologie, Frauenklinik des Universitätsklinikums Erlangen, Erlangen
,
P. Wieacker
6   Institut für Humangenetik, Universitätsklinikum Münster, Münster
,
J. Kratzsch
7   Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik der Universität Leipzig, Leipzig
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
21. Dezember 2015 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Purpose: This guideline of the German Society of Pediatric Endocrinology and Diabetology (DGKED) is designed to be expertsʼ opinion on the current concept of prenatal therapy for congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). Several scientific medical societies have also participated in the guideline. It aims to offer guidance to physicians when they counsel affected families about prenatal therapy. Methods: The experts commissioned by the medical societies developed a consensus in an informal process. The consensus was subsequently confirmed by the steering committees of the respective medical societies. Recommendations: Prenatal CAH therapy is an experimental therapy. We recommend designing and using standardized protocols for the prenatal diagnosis, therapy and long-term follow-up of women and children treated prenatally with dexamethasone. If long-term follow-up is not possible, then prenatal therapy should not be performed.

Zusammenfassung

Ziel: Diese Leitlinie der Deutschen Gesellschaft für Kinderendokrinologie und -diabetologie (DGKED) e. V. unter Beteiligung mehrerer Fachgesellschaften wie der DGGG wurde als Stellungnahme von Experten zum derzeitigen Stand der pränatalen Therapie des Adrenogenitalen Syndroms mit 21-Hydroxylasedefekt konzipiert. Sie soll den beteiligten Ärzten als Orientierungshilfe bei der Entscheidung dienen, um betroffene Familien bei der pränatalen Therapie besser beraten zu können. Methoden: Die von den beteiligten Fachgesellschaften beauftragten Experten entwickelten in einem informellen Prozess einen Konsensus. Anschließend wurde der Konsensus von den Vorständen der beteiligten Fachgesellschaften bestätigt. Empfehlungen: Die pränatale AGS-Therapie ist eine experimentelle Therapie. Für die pränatale Diagnostik und Therapie sollen standardisierte Protokolle entworfen und verwendet werden. Dies gilt auch für die Langzeitnachsorge der Frauen und Kinder, die pränatal mit Dexamethason behandelt wurden. Wenn die Langzeitnachsorge der Kinder nicht gewährleistet ist, dann soll auch keine pränatale Therapie durchgeführt werden.

Key words

CAH - prenatal therapy - dexamethasone - off-label use

Schlüsselwörter

AGS - pränatale Therapie - Dexamethason - Off-Label-Use

* German Society of Pediatric Endocrinology and Diabetology (Deutsche Gesellschaft für Kinderendokrinologie und -diabetologie)


Supporting Information

 

  • References

  • 1 New MI. Prenatal treatment of congenital adrenal hyperplasia. The United States experience. Endocrinol Metab Clin North Am 2001; 30: 1-13
    CrossrefPubMedGoogle Scholar
  • 2 Forest MG, Betuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res 1989; 15: 277-301
    CrossrefPubMedGoogle Scholar
  • 3 Forest MG, Dörr HG. on behalf of ESPE. Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 2003; 13: 252-259
    CrossrefPubMedGoogle Scholar
  • 4 New MI, Carlson A, Obeid J et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001; 86: 5651-5657
    CrossrefPubMedGoogle Scholar
  • 5 Wudy SA, Homoki J, Teller WM. Successful prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Pediatr 1994; 153: 556-559
    CrossrefPubMedGoogle Scholar
  • 6 Speiser PW, Azziz R, Baskin LS et al. A summary of the Endocrine Society clinical practice guidelines on congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Int J Pediatr Endocrinol 2010; 2010: 494173
    CrossrefPubMedGoogle Scholar
  • 7 Lajic S, Nordenstrom A, Ritzen EM et al. Prenatal treatment of congenital adrenal hyperplasia. Eur J Endocrinol 2004; 151 (Suppl. 03) U63-U69
    CrossrefPubMedGoogle Scholar
  • 8 Tardy-Guidollet V, Menassa R, Costa JM et al. New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002–2011). J Clin Endocrinol Metab 2014; 99: 1180-1188
    CrossrefPubMedGoogle Scholar
  • 9 New MI, Tong YK, Yuen T et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab 2014; 99: E1022-E1030
    CrossrefPubMedGoogle Scholar
  • 10 Avent ND, Chitty LS. Non-invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 2006; 26: 598-603
    CrossrefPubMedGoogle Scholar
  • 11 Meaney C, Norbury G. Non-invasive prenatal diagnosis. Methods Mol Biol 2011; 688: 155-172
    PubMedGoogle Scholar
  • 12 Beck JC, Johnson JW. Maternal administration of glucocorticoids. Clin Obstet Gynecol 1980; 23: 93-113
    CrossrefPubMedGoogle Scholar
  • 13 Speiser PW. Prenatal treatment of congenital adrenal hyperplasia. J Urol 1999; 162: 534-536
    CrossrefPubMedGoogle Scholar
  • 14 Claahsen-van der Grinten HL, Stikkelbroeck NM, Otten BJ et al. Congenital adrenal hyperplasia–pharmacologic interventions from the prenatal phase to adulthood. Pharmacol Ther 2011; 132: 1-14
    CrossrefPubMedGoogle Scholar
  • 15 Coleman MA, Honour JW. Reduced maternal dexamethasone dosage for the prenatal treatment of congenital adrenal hyperplasia. BJOG 2004; 111: 176-178
    CrossrefPubMedGoogle Scholar
  • 16 Dörr HG, Sippell WG, Willig RP. [Prenatal diagnosis and therapy of adrenogenital syndrome with 21-hydroxylase deficiency]. Geburtsh Frauenheilk 1992; 52: 586-588
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 17 Forest MG, David M. Prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a 10 year experience. Indian J Pediatr 1992; 59: 515-522
    CrossrefPubMedGoogle Scholar
  • 18 New MI. Vindication of prenatal diagnosis and treatment of congenital adrenal hyperplasia with low-dose dexamethasone. Am J Bioeth 2010; 10: 67-68
    PubMedGoogle Scholar
  • 19 Nimkarn S, New MI. Prenatal diagnosis and treatment of congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Nat Clin Pract Endocrinol Metab 2007; 3: 405-413
    CrossrefPubMedGoogle Scholar
  • 20 Nimkarn S, New MI. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a paradigm for prenatal diagnosis and treatment. Ann N Y Acad Sci 2010; 1192: 5-11
    CrossrefPubMedGoogle Scholar
  • 21 Hirvikoski T, Nordenstrom A, Wedell A et al. Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. J Clin Endocrinol Metab 2012; 97: 1881-1883
    CrossrefPubMedGoogle Scholar
  • 22 Miller WL, Witchel SF. Prenatal treatment of congenital adrenal hyperplasia: risks outweigh benefits. Am J Obstet Gynecol 2013; 208: 354-359
    CrossrefPubMedGoogle Scholar
  • 23 Mercado AB, Wilson RC, Cheng KC et al. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995; 80: 2014-2020
    PubMedGoogle Scholar
  • 24 New MI. Prenatal treatment of congenital adrenal hyperplasia: author differs with technical report. Pediatrics 2001; 107: 804
    PubMedGoogle Scholar
  • 25 New MI, Abraham M, Yuen T et al. An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia. Semin Reprod Med 2012; 30: 396-399
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 26 Lajic S, Nordenstrom A, Hirvikoski T. Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. Endocr Dev 2008; 13: 82-98
    PubMedGoogle Scholar
  • 27 Trautman PD, Meyer-Bahlburg HF, Postelnek J et al. Mothersʼ reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia. J Psychosom Obstet Gynaecol 1996; 17: 175-181
    CrossrefPubMedGoogle Scholar
  • 28 Lajic S, Wedell A, Bui TH et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998; 83: 3872-3880
    PubMedGoogle Scholar
  • 29 Meyer-Bahlburg HF, Dolezal C, Baker SW et al. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004; 89: 610-614
    CrossrefPubMedGoogle Scholar
  • 30 Meyer-Bahlburg HF, Dolezal C, Baker SW et al. Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav 2004; 33: 97-104
    CrossrefPubMedGoogle Scholar
  • 31 Hirvikoski T, Nordenstrom A, Lindholm T et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007; 92: 542-548
    CrossrefPubMedGoogle Scholar
  • 32 Merce Fernandez-Balsells M, Muthusamy K, Smushkin G et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 73: 436-444
    PubMedGoogle Scholar
  • 33 Meyer-Bahlburg HF, Dolezal C, Haggerty R et al. Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol 2012; 167: 103-110
    CrossrefPubMedGoogle Scholar
  • 34 Maryniak A, Ginalska-Malinowska M, Bielawska A et al. Cognitive and social function in girls with congenital adrenal hyperplasia – Influence of prenatally administered dexamethasone. Child Neuropsychol 2014; 20: 60-70
    CrossrefPubMedGoogle Scholar
  • 35 Khulan B, Drake AJ. Glucocorticoids as mediators of developmental programming effects. Best Pract Res Clin Endocrinol Metab 2012; 26: 689-700
    CrossrefPubMedGoogle Scholar
  • 36 National Council on Nutrition and Physical Activity in Norway. Extract from the Norwegian National Report on Physical Activity and Health. Scand J Med Sci Sports 2001; 11: 255-257
    CrossrefPubMedGoogle Scholar
  • 37 Seckl JR. Glucocorticoid programming of the fetus; adult phenotypes and molecular mechanisms. Mol Cell Endocrinol 2001; 185: 61-71
    CrossrefPubMedGoogle Scholar
  • 38 Seckl JR, Miller WL. How safe is long-term prenatal glucocorticoid treatment?. JAMA 1997; 277: 1077-1079
    CrossrefPubMedGoogle Scholar
  • 39 de Vries A, Holmes MC, Heijnis A et al. Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function. J Clin Invest 2007; 117: 1058-1067
    CrossrefPubMedGoogle Scholar
  • 40 Vos AA, Bruinse HW. Congenital adrenal hyperplasia: do the benefits of prenatal treatment defeat the risks?. Obstet Gynecol Surv 2010; 65: 196-205
    CrossrefPubMedGoogle Scholar